A Rare Pathological Phenotype of Endometrioid Serous and Clear-Cell Ovarian Cancer with PIK3CA Mutations in Relation to The Excellent Response of Alpelisib
Patients with metastatic ovarian cancer who develop resistance to standard therapy with or without platinum need to search for other therapeutic choices. Therefore, identifying genetic alterations and selecting an approach to treatment using precision medicine techniques are important. In a patient...
Main Authors: | Ertugrul Bayram, Ghanim Khatib, Burak Guney, Emine Kilicbagir, Huru Rabia Gulec, Ibrahim Boga, Semra Paydas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/14/8/1632 |
Similar Items
-
Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
by: Ari Raphael, et al.
Published: (2022-09-01) -
Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines
by: Jiah Yeom, et al.
Published: (2023-11-01) -
Alpelisib-induced thyroiditis in a patient with metastatic breast cancer: Is routine monitoring of thyroid function required?
by: Calvin R Flynn, et al.
Published: (2023-03-01) -
Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
by: Mohamed E. Shaker, et al.
Published: (2023-08-01) -
Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences
by: Yuhao Ye, et al.
Published: (2023-03-01)